Non-Small Cell Lung Cancer

A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.

Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.

The FDA expanded accelerated approval of sevabertinib to previously untreated HER2-mutant non-squamous NSCLC, citing a 75% response rate in trial data.

Review finds 91 new lung cancer screening and pulmonary nodule AI tools, but few get external validation or calibration, risking flawed LDCT decisions.

The AACR roadmap spotlights LDCT screening, ctDNA MRD monitoring, and new NSCLC/SCLC therapies like DLL3 tarlatamab to close survival gaps.

Basement membrane composition actively drives NSCLC invasion, metastasis, and treatment resistance, a review finds, rather than serving as passive scaffolding.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models, citing Taiwan's TALENT cohort as evidence broader eligibility finds cancer earlier.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

In patients with NSCLC, 3+1 lymph node sampling was not linked to higher postoperative complications, supporting guideline adherence.